Protective Role of microRNA May Hold Therapeutic Potential for ALS, Study Shows
A small molecule known as mir-494-3p might play a protective role in the survival of motor nerve cells, a discovery…
Articles by Iqra Mumal, MSc
FUS Mutations Likely Cause ALS by Preventing Repair of Oxidative Damage in DNA
FUS — a protein mutated in some amyotrophic lateral sclerosis patients — plays a key role in the mechanism that…
Noxopharm and Nyrada Discover Potent Inhibitor of Key Protein Involved in ALS, Other Conditions
The pharmaceutical development company Noxopharm and its majority-owned subsidiary, U.S. biotechnology firm Nyrada, have discovered a potent inhibitor of…
New Method Described in Thesis Can Help Characterize and Target Misfolded Protein in ALS
A newly developed method can help characterize the types of misfolded proteins present in patients with amyotrophic lateral sclerosis…
Nerve Cell Death Signaling May Hold Key to Treating ALS, Other Diseases, Study Finds
A new process by which pro-death signaling is sent to nerve cells may hold the key for treating neurodegenerative diseases…
Systems Using Brain Signals to Communicate Can Help Advanced ALS Patients, But Improvements Needed
The Wadsworth Brain-Computer Interface (BCI) can help amyotrophic lateral sclerosis (ALS) patients who are severely disabled to communicate while in…
Tikomed Gets OK to Begin Phase 2 Trial in UK Testing Investigational ALS Therapy ILB
The Medicines and Healthcare products Regulatory Agency in the United Kingdom has granted permission to Tikomed to begin…
Extracts from Medicinal Plant Improved Motor Function, Delayed Disease Worsening in ALS Mice, Study Finds
Treatment with extracts from the Withania somnifera plant improved motor performance and delayed disease progression in mice with amyotrophic lateral sclerosis (ALS), according to…
Arrows and Colors Test Measures Cognition in Severe ALS Patients
A newly developed test, known as the arrows and colors cognitive test, can be used to measure cognition in amyotrophic…
Orphazyme Doses First ALS Patient in Phase 3 Trial of Arimoclomol
The first patient has been dosed in a Phase 3 clinical trial (NCT03491462) evaluating the effectiveness of Orphazyme’s…